News from ASCO 2018

Balic, M; Dedic, N; De Mattos-Arruda, L; Gampenrieder, S BREAST CARE. 2018; 13(4): 298-302.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.

Domenyuk, V; Gatalica, Z; Santhanam, R; Wei, XX; Stark, A; Kennedy, P; Toussaint, B; Levenberg, S; Wang, J; Xiao, NQ; Greil, R; Rinnerthaler, G; Gampenrieder, SP; Heimberger, AB; Berry, DA; Barker, A; Quackenbush, J; Marshall, JL; Poste, G; Vacirca, JL; Vidal, GA; Schwartzberg, LS; Halbert, DD; Voss, A; Magee, D; Miglarese, MR; Famulok, M; Mayer, G; Spetzler, D NAT COMMUN. 2018; 9(1): 1219

Non-Hodgkin lymphoma risk in adults living with HIV across five continents The AIDS-defining Cancer Project Working Group of leDEA and COHERE in EuroCoord

Rohner, E; Butikofer, L; Schmidlin, K; Sengayi, M; Maskew, M; Giddy, J; Moore, RD; Goedert, JJ; Gill, MJ; Silverberg, MJ; Patel, P; Castilho, J; Hoy, J; Sohn, A; Bani-Sadr, F; Taylor, N; Paparizos, V; Le Moing, V; Bonnet, F; Verbon, A; Vehreschild, JJ; Post, FA; Sabin, C; Mocroft, A; Dronda, F; Obel, N; Grabar, S; Spagnuolo, V; Antinori, A; Quiros-Rol-Dan, E; Mussini, C; Miro, JM; Meyer, L; Hasse, B; Konopnicki, D; Roca, B; Boue, F; Barger, D; Raben, D; Clifford, GM; Franceschi, S; Brockmeyer, N; Egger, M; Bohlius, J AIDS. 2018; 32(18): 2777-2786.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino, E; Benedetti, D; Herman, SEM; Ten Hacken, E; Ahn, IE; Chaffee, KG; Rossi, FM; Dal Bo, M; Bulian, P; Bomben, R; Bayer, E; Härzschel, A; Gutjahr, JC; Postorino, M; Santinelli, E; Ayed, A; Zaja, F; Chiarenza, A; Pozzato, G; Chigaev, A; Sklar, LA; Burger, JA; Ferrajoli, A; Shanafelt, TD; Wiestner, A; Del Poeta, G; Hartmann, TN; Gattei, V; Zucchetto, A; J Exp Med. 2018; 215(2):681-697

Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia.

Schubert, M; Hackl, H; Gassner, FJ; Greil, R; Geisberger, R; PLoS One. 2018; 13(12): e0208753

Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.

Schlick, K; Magnes, T; Ratzinger, L; Jaud, B; Weiss, L; Melchardt, T; Greil, R; Egle, A; PLoS One. 2018; 13(11): e0206688

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.

Westphal, T; Rinnerthaler, G; Gampenrieder, SP; Niebauer, J; Thaler, J; Pfob, M; Fuchs, D; Riedmann, M; Mayr, B; Reich, B; Melchardt, T; Mlineritsch, B; Pleyer, L; Greil, R; Cancer Med. 2018; 7(12):596-5972

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial

Paschka, P; Schlenk, RF; Weber, D; Benner, A; Bullinger, L; Heuser, M; Gaidzik, VI; Thol, F; Agrawal, M; Teleanu, V; Lubbert, M; Fiedler, W; Radsak, M; Krauter, J; Horst, HA; Greil, R; Mayer, K; Kundgen, A; Martens, U; Heil, G; Salih, HR; Hertenstein, B; Schwanen, C; Wulf, G; Lange, E; Pfreundschuh, M; Ringhoffer, M; Girschikofsky, M; Heinicke, T; Kraemer, D; Gohring, G; Ganser, A; Dohner, K; Dohner, H LEUKEMIA. 2018; 32(7): 1621-1630.

Remission maintenance treatment options in chronic lymphocytic leukemia.

Egle, A; Pleyer, L; Melchardt, T; Hartmann, TN; Greil, R; Cancer Treat Rev. 2018; 70:56-66

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.

Gutjahr, JC; Szenes, E; Tschech, L; Asslaber, D; Schlederer, M; Roos, S; Yu, X; Girbl, T; Sternberg, C; Egle, A; Aberger, F; Alon, R; Kenner, L; Greil, R; Orian-Rousseau, V; Hartmann, TN; Blood. 2018; 131(12): 1337-1349.